documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
727,510 rows sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
These facets timed out: agency_id, document_type
posted_year >30
- 2024 42,567
- 2021 42,429
- 2016 42,286
- 2022 41,948
- 2017 41,782
- 2019 41,555
- 2023 39,003
- 2020 37,917
- 2015 34,294
- 2014 31,844
- 2018 31,216
- 2025 31,121
- 2013 27,700
- 2011 27,021
- 2010 23,222
- 2012 22,928
- 2008 22,557
- 2009 22,117
- 2006 21,676
- 2007 18,172
- 2004 18,054
- 2005 15,437
- 2003 12,180
- 1995 6,422
- 2002 5,191
- 2026 4,918
- 1999 4,076
- 2001 3,556
- 1998 3,450
- 1994 3,308
- …
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USDA_FRDOC_0001-3267 | USDA | Recently Posted USDA Rules and Notices. USDA_FRDOC_0001 | Agency Information Collection Activities; Proposals, Submissions, and Approvals | Notice | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T18:14:56Z | 2026-03979 | 0 | 0 | 09000064b91e323f | ||
| FWS-R5-MB-2025-1497-0001 | FWS | Agency Information Collection Activities; Northeast Region Hunter Participation Surveys (OMB Cont. No. 1018-0195) FWS-R5-MB-2025-1497 | Agency Information Collection Activities; Northeast Region Hunter Participation Surveys | Notice | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T17:57:25Z | 2026-03946 | 1 | 0 | 09000064b91df85a | |
| FWS-R5-MB-2025-1497-0002 | FWS | Agency Information Collection Activities; Northeast Region Hunter Participation Surveys (OMB Cont. No. 1018-0195) FWS-R5-MB-2025-1497 | 3-2558 Spring Turkey Hunter Participation Survey Rev 12-2025 w-changes highlighted 12192025 | Supporting & Related Material | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T18:14:43Z | 0 | 0 | 09000064b91df736 | ||||
| FWS-R5-MB-2025-1497-0003 | FWS | Agency Information Collection Activities; Northeast Region Hunter Participation Surveys (OMB Cont. No. 1018-0195) FWS-R5-MB-2025-1497 | 3-2557 Hunter Participation Survey Rev 12-2025 w-changes highlighted 12192025 | Supporting & Related Material | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T18:14:43Z | 0 | 0 | 09000064b91df737 | ||||
| FDA-2026-H-1967-0001 | FDA | FDA-2026-H-1967 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T00:52:27Z | 0 | 0 | 09000064b91e2c80 | ||
| FDA-2026-P-2144-0004 | FDA | FDA-2026-P-2144 | Attachment 2 | Supporting & Related Material | Background Material | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T22:06:16Z | 0 | 0 | 09000064b91e2fcb | |||
| FDA-2026-H-1966-0001 | FDA | FDA-2026-H-1966 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T00:42:04Z | 0 | 0 | 09000064b91e3d80 | ||
| FDA-2026-H-1789-0001 | FDA | FDA-2026-H-1789 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T23:48:46Z | 0 | 0 | 09000064b91e3834 | ||
| FDA-2026-N-1628-0001 | FDA | FDA-2026-N-1628 | International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Scheduling Recommendations; N-Pyrrolidino Isotonitazene; N-Desethyl Etonitazene; Coca Leaf; MDMB-FUBINACA; Request for Comments | Notice | Request for Comments | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-03-06T04:59:59Z | 2026-02-27T20:18:13Z | 2026-03914 | 1 | 0 | 09000064b91e31af |
| FDA-2007-D-0369-2525 | FDA | FDA-2007-D-0369 | PSG_219104 - Draft Guidance on Letermovir | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:52:13Z | 1 | 0 | 09000064b91e01dd | |
| FDA-2007-D-0369-2524 | FDA | FDA-2007-D-0369 | PSG_219097 - Draft Guidance on Imatinib Mesylate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:51:42Z | 1 | 0 | 09000064b91e01db | |
| FDA-2007-D-0369-2521 | FDA | FDA-2007-D-0369 | PSG_218550 - Draft Guidance on Entrectinib | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:50:35Z | 1 | 0 | 09000064b91e01d5 | |
| FDA-2007-D-0369-2519 | FDA | FDA-2007-D-0369 | PSG_218316 - Draft Guidance on Semaglutide | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:49:49Z | 1 | 0 | 09000064b91e01d1 | |
| FDA-2007-D-0369-2526 | FDA | FDA-2007-D-0369 | PSG_220073 - Draft Guidance on Apixaban | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:52:29Z | 1 | 0 | 09000064b91e01f3 | |
| FDA-2007-D-0369-2437 | FDA | FDA-2007-D-0369 | PSG_019758 - Draft Guidance on Clozapine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:20:28Z | 1 | 0 | 09000064b91df4ce | |
| FDA-2007-D-0369-2433 | FDA | FDA-2007-D-0369 | PSG_018731 - Draft Guidance on Buspirone Hydrochloride | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:19:11Z | 1 | 0 | 09000064b91df467 | |
| FDA-2007-D-0369-2445 | FDA | FDA-2007-D-0369 | PSG_020310 - Draft Guidance on Ketoconazole | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:22:59Z | 1 | 0 | 09000064b91df4ee | |
| FDA-2007-D-0369-2452 | FDA | FDA-2007-D-0369 | PSG_020870 - Draft Guidance on Estradiol; Norethindrone Acetate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:25:03Z | 1 | 0 | 09000064b91e0106 | |
| FDA-2007-D-0369-2463 | FDA | FDA-2007-D-0369 | PSG_021590 - Draft Guidance on Clozapine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:30:34Z | 1 | 0 | 09000064b91e0127 | |
| FDA-2007-D-0369-2471 | FDA | FDA-2007-D-0369 | PSG_022549 - Draft Guidance on Loxapine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:33:45Z | 1 | 0 | 09000064b91e0138 | |
| FDA-2007-D-0369-2499 | FDA | FDA-2007-D-0369 | PSG_214187 - Draft Guidance on Sofosbuvir; Velpatasvir | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:43:04Z | 1 | 0 | 09000064b91e018e | |
| FDA-2007-D-0369-2474 | FDA | FDA-2007-D-0369 | PSG_202155 - Draft Guidance on Apixaban | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:34:51Z | 1 | 0 | 09000064b91e013e | |
| FDA-2007-D-0369-2504 | FDA | FDA-2007-D-0369 | PSG_215110 - Draft Guidance on Glecaprevir; Pibrentasvir | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:44:51Z | 1 | 0 | 09000064b91e0198 | |
| FDA-2007-D-0369-2502 | FDA | FDA-2007-D-0369 | PSG_214826 - Draft Guidance on Lorazepam | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:44:20Z | 1 | 0 | 09000064b91e0194 | |
| FDA-2007-D-0369-2487 | FDA | FDA-2007-D-0369 | PSG_210136 - Draft Guidance on Buprenorphine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:39:03Z | 1 | 0 | 09000064b91e016c | |
| FDA-2026-H-1924-0001 | FDA | FDA-2026-H-1924 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T17:54:21Z | 0 | 0 | 09000064b91e2df0 | ||
| FDA-2026-H-1422-0001 | FDA | FDA-2026-H-1422 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T18:07:36Z | 0 | 0 | 09000064b91df74e | ||
| FDA-2025-P-4612-0004 | FDA | FDA-2025-P-4612 | Final Response Letter from FDA CDER to Arnall Golden Gregory, LLP | Other | Denial of Petition | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T20:03:31Z | 0 | 0 | 09000064b91e0bd2 | ||
| FDA-2007-D-0369-2518 | FDA | FDA-2007-D-0369 | PSG_217514 - Draft Guidance on Dabrafenib Mesylate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:49:32Z | 1 | 0 | 09000064b91e01cf | |
| FDA-2007-D-0369-2505 | FDA | FDA-2007-D-0369 | PSG_215352 - Draft Guidance on Phenylephrine Hydrochloride; Tropicamide | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:45:07Z | 1 | 0 | 09000064b91e019a | |
| FDA-2007-D-0369-2470 | FDA | FDA-2007-D-0369 | PSG_022395 - Draft Guidance on Capsaicin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:33:25Z | 1 | 0 | 09000064b91e0135 | |
| FDA-2007-D-0369-2468 | FDA | FDA-2007-D-0369 | PSG_022198 - Draft Guidance on Granisetron | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:32:47Z | 1 | 0 | 09000064b91e0131 | |
| FDA-2007-D-0369-2483 | FDA | FDA-2007-D-0369 | PSG_208036 - Draft Guidance on Barium Sulfate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:37:51Z | 1 | 0 | 09000064b91e015a | |
| FDA-2007-D-0369-2465 | FDA | FDA-2007-D-0369 | PSG_021986 - Draft Guidance on Dasatinib | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:31:13Z | 1 | 0 | 09000064b91e012b | |
| FDA-2007-D-0369-2478 | FDA | FDA-2007-D-0369 | PSG_205395 - Draft Guidance on Cobicistat; Darunavir Ethanolate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:36:14Z | 1 | 0 | 09000064b91e0150 | |
| FDA-2007-D-0369-2430 | FDA | FDA-2007-D-0369 | PSG_017628 - Draft Guidance on Tolmetin Sodium | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:18:11Z | 1 | 0 | 09000064b91df461 | |
| FDA-2007-D-0369-2450 | FDA | FDA-2007-D-0369 | PSG_020612 - Draft Guidance on Lidocaine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:24:27Z | 1 | 0 | 09000064b91df4f8 | |
| FDA-2007-D-0369-2451 | FDA | FDA-2007-D-0369 | PSG_020831 - Draft Guidance on Formoterol Fumarate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:24:44Z | 1 | 0 | 09000064b91e0104 | |
| FDA-2007-D-0369-2455 | FDA | FDA-2007-D-0369 | PSG_021258 - Draft Guidance on Estradiol; Levonorgestrel | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:25:50Z | 1 | 0 | 09000064b91e010c | |
| FDA-2007-D-0369-2436 | FDA | FDA-2007-D-0369 | PSG_019081 - Draft Guidance on Estradiol | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:20:10Z | 1 | 0 | 09000064b91df4cc | |
| FDA-2026-H-1972-0001 | FDA | FDA-2026-H-1972 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T01:27:00Z | 0 | 0 | 09000064b91e451b | ||
| FDA-2026-H-1968-0001 | FDA | FDA-2026-H-1968 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T01:29:56Z | 0 | 0 | 09000064b91e451e | ||
| FDA-1991-N-0191-0001 | FDA | Civil money penalties:biologics, drugs and medical devices FDA-1991-N-0191 | CIVIL MONEY PENALTIES: BIOLOGICS, DRUGS, AND MEDICAL DEVICES | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 1993-07-27T03:59:59Z | 2026-02-28T01:41:45Z | 93-12314 | 0 | 0 | 090000648052de75 |
| FDA-2026-H-1958-0001 | FDA | FDA-2026-H-1958 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T23:55:07Z | 0 | 0 | 09000064b91e3874 | ||
| FDA-2026-H-1786-0001 | FDA | FDA-2026-H-1786 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T22:57:13Z | 0 | 0 | 09000064b91e30c0 | ||
| FDA-2026-P-2144-0001 | FDA | FDA-2026-P-2144 | Suitability Petition from Hyman, Phelps & McNamara, P.C. | Other | Petition(s) | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T22:05:51Z | 1 | 0 | 09000064b91e3853 | ||
| FDA-2026-P-1300-0005 | FDA | FDA-2026-P-1300 | Suitability Petition Amendment from APDM Pharmaceuticals Private Limited | Other | Amendment | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T23:32:34Z | 1 | 0 | 09000064b91e3c62 | ||
| FDA-2026-N-1486-0001 | FDA | FDA-2026-N-1486 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZYCUBO (Copper Histidinate) | Notice | Announcement | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T20:11:11Z | 2026-03925 | 0 | 0 | 09000064b91e323b | |
| FDA-2007-D-0369-2458 | FDA | FDA-2007-D-0369 | PSG_021351 - Draft Guidance on Oxybutynin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:27:00Z | 1 | 0 | 09000064b91e011d | |
| FDA-2007-D-0369-2510 | FDA | FDA-2007-D-0369 | PSG_216318 - Draft Guidance on Testosterone Cypionate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:46:43Z | 1 | 0 | 09000064b91e01b1 | |
| FDA-2007-D-0369-2513 | FDA | FDA-2007-D-0369 | PSG_216675 - Draft Guidance on Perfluorohexyloctane | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:47:39Z | 1 | 0 | 09000064b91e01b8 | |
| FDA-2007-D-0369-2462 | FDA | FDA-2007-D-0369 | PSG_021588 - Draft Guidance on Imatinib Mesylate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:29:47Z | 1 | 0 | 09000064b91e0125 | |
| FDA-2007-D-0369-2449 | FDA | FDA-2007-D-0369 | PSG_020538 - Draft Guidance on Estradiol | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:24:10Z | 1 | 0 | 09000064b91df4f6 | |
| FDA-2007-D-0369-2431 | FDA | FDA-2007-D-0369 | PSG_017874 - Draft Guidance on Scopolamine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:18:30Z | 1 | 0 | 09000064b91df463 | |
| FDA-2007-D-0369-2434 | FDA | FDA-2007-D-0369 | PSG_018859 - Draft Guidance on Ribavirin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:19:33Z | 1 | 0 | 09000064b91df4c8 | |
| FDA-2007-D-0369-2496 | FDA | FDA-2007-D-0369 | PSG_213004 - Draft Guidance on Amoxicillin; Omeprazole Magnesium; Rifabutin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:41:55Z | 1 | 0 | 09000064b91e0188 | |
| FDA-2007-D-0369-2477 | FDA | FDA-2007-D-0369 | PSG_204017 - Draft Guidance on Ethinyl Estradiol; Levonorgestrel | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:35:51Z | 1 | 0 | 09000064b91e014e | |
| FDA-2007-D-0369-2491 | FDA | FDA-2007-D-0369 | PSG_212268 - Draft Guidance on Asenapine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:40:16Z | 1 | 0 | 09000064b91e017e | |
| FDA-2007-D-0369-2501 | FDA | FDA-2007-D-0369 | PSG_214522 - Draft Guidance on Tadalafil | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:44:01Z | 1 | 0 | 09000064b91e0192 | |
| FDA-2007-D-0369-2485 | FDA | FDA-2007-D-0369 | PSG_208171 - Draft Guidance on Ferric Derisomaltose | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:38:28Z | 1 | 0 | 09000064b91e015e | |
| FDA-2007-D-0369-2472 | FDA | FDA-2007-D-0369 | PSG_050440 - Draft Guidance on Cephalexin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:34:04Z | 1 | 0 | 09000064b91e013a | |
| FDA-2007-D-0369-2498 | FDA | FDA-2007-D-0369 | PSG_213953 - Draft Guidance on Testosterone Undecanoate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:42:31Z | 1 | 0 | 09000064b91e018c | |
| FDA-2007-D-0369-2493 | FDA | FDA-2007-D-0369 | PSG_212306 - Draft Guidance on Selinexor | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:40:55Z | 1 | 0 | 09000064b91e0182 | |
| FDA-2007-D-0369-2503 | FDA | FDA-2007-D-0369 | PSG_215039 - Draft Guidance on Alpelisib | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:44:36Z | 1 | 0 | 09000064b91e0196 | |
| FDA-2007-D-0369-2492 | FDA | FDA-2007-D-0369 | PSG_212304 - Draft Guidance on Donepezil Hydrochloride | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:40:33Z | 1 | 0 | 09000064b91e0180 | |
| FDA-2026-H-1964-0001 | FDA | FDA-2026-H-1964 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T01:59:24Z | 0 | 0 | 09000064b91e4522 | ||
| FDA-1991-N-0191-0002 | FDA | Civil money penalties:biologics, drugs and medical devices FDA-1991-N-0191 | Request for Extension from Health Industry Manufacturers Association | Other | Request for Extension | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T01:44:11Z | 0 | 0 | 090000648052de80 | ||
| FDA-1991-N-0191-0010 | FDA | Civil money penalties:biologics, drugs and medical devices FDA-1991-N-0191 | Civil Money Penalties; Biologics, Drugs, and Medical Devices; Extension of Comment Period; Correction and Addition Period; Correction and Addition | Notice | Notice of Extension | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 1993-08-26T03:59:59Z | 2026-02-28T02:00:09Z | 93-17833 | 0 | 0 | 090000648052deaf |
| FDA-2026-P-2144-0002 | FDA | FDA-2026-P-2144 | Acknowledgement Letter from FDA DMB to Hyman, Phelps & McNamara, P.C. | Other | Acknowledgement Letter/Receipt | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T22:06:07Z | 0 | 0 | 09000064b91e3859 | ||
| FDA-2026-P-1300-0007 | FDA | FDA-2026-P-1300 | Attachment 2 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Approval Letter | Supporting & Related Material | Background Material | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T23:33:00Z | 0 | 0 | 09000064b91e3e1a | |||
| FDA-2007-D-0369-2456 | FDA | FDA-2007-D-0369 | PSG_021306 - Draft Guidance on Buprenorphine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:26:18Z | 1 | 0 | 09000064b91e0119 | |
| FDA-2007-D-0369-2428 | FDA | FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T19:14:17Z | 2026-03963 | 0 | 0 | 09000064b91e3271 | |
| FDA-2026-H-1971-0001 | FDA | FDA-2026-H-1971 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T01:24:53Z | 0 | 0 | 09000064b91e30c9 | ||
| FDA-2026-H-1965-0001 | FDA | FDA-2026-H-1965 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-28T00:10:55Z | 0 | 0 | 09000064b91e3d4b | ||
| FDA-2026-P-1300-0006 | FDA | FDA-2026-P-1300 | Attachment 1 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Package Insert | Supporting & Related Material | Background Material | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T23:32:57Z | 0 | 0 | 09000064b91e3e19 | |||
| FDA-2026-H-1785-0001 | FDA | FDA-2026-H-1785 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T22:16:22Z | 0 | 0 | 09000064b91e37f3 | ||
| FDA-2026-H-1782-0001 | FDA | FDA-2026-H-1782 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T23:01:08Z | 0 | 0 | 09000064b91e3e15 | ||
| FDA-2026-H-1961-0001 | FDA | FDA-2026-H-1961 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T22:13:46Z | 0 | 0 | 09000064b91e2bfe | ||
| FDA-2026-H-1960-0001 | FDA | FDA-2026-H-1960 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T21:40:48Z | 0 | 0 | 09000064b91e2fce | ||
| FDA-2023-N-0119-0020 | FDA | FDA-2023-N-0119 | Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments | Notice | Request for Comments | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-07-11T03:59:59Z | 2026-02-27T19:57:39Z | 2026-03961 | 1 | 0 | 09000064b91e326c |
| FDA-2007-D-0369-2480 | FDA | FDA-2007-D-0369 | PSG_206968 - Draft Guidance on Acetaminophen | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:36:59Z | 1 | 0 | 09000064b91e0154 | |
| FDA-2007-D-0369-2515 | FDA | FDA-2007-D-0369 | PSG_217202 - Draft Guidance on Landiolol Hydrochloride | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:48:39Z | 1 | 0 | 09000064b91e01bc | |
| FDA-2007-D-0369-2517 | FDA | FDA-2007-D-0369 | PSG_217370 - Draft Guidance on Acoltremon | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:49:14Z | 1 | 0 | 09000064b91e01cd | |
| FDA-2007-D-0369-2514 | FDA | FDA-2007-D-0369 | PSG_216962 - Draft Guidance on Foscarbidopa; Foslevodopa | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:48:20Z | 1 | 0 | 09000064b91e01ba | |
| FDA-2007-D-0369-2523 | FDA | FDA-2007-D-0369 | PSG_219016 - Draft Guidance on Rilpivirine Hydrochloride | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:51:25Z | 1 | 0 | 09000064b91e01d9 | |
| FDA-2007-D-0369-2482 | FDA | FDA-2007-D-0369 | PSG_207962 - Draft Guidance on Lidocaine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:37:34Z | 1 | 0 | 09000064b91e0158 | |
| FDA-2007-D-0369-2476 | FDA | FDA-2007-D-0369 | PSG_203479 - Draft Guidance on Clozapine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:35:30Z | 1 | 0 | 09000064b91e014c | |
| FDA-2007-D-0369-2495 | FDA | FDA-2007-D-0369 | PSG_212526 - Draft Guidance on Alpelisib | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:41:39Z | 1 | 0 | 09000064b91e0186 | |
| FDA-2007-D-0369-2484 | FDA | FDA-2007-D-0369 | PSG_208143 - Draft Guidance on Barium Sulfate | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:38:13Z | 1 | 0 | 09000064b91e015c | |
| FDA-2007-D-0369-2494 | FDA | FDA-2007-D-0369 | PSG_212516 - Draft Guidance on Duloxetine Hydrochloride | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:41:20Z | 1 | 0 | 09000064b91e0184 | |
| FDA-2007-D-0369-2500 | FDA | FDA-2007-D-0369 | PSG_214410 - Draft Guidance on Baloxavir Marboxil | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:43:31Z | 1 | 0 | 09000064b91e0190 | |
| FDA-2026-H-1922-0001 | FDA | FDA-2026-H-1922 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T18:45:55Z | 0 | 0 | 09000064b91dfe38 | ||
| FDA-2007-D-0369-2454 | FDA | FDA-2007-D-0369 | PSG_021234 - Draft Guidance on Diclofenac Epolamine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:25:35Z | 1 | 0 | 09000064b91e010a | |
| FDA-2007-D-0369-2448 | FDA | FDA-2007-D-0369 | PSG_020489 - Draft Guidance on Testosterone | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:23:57Z | 1 | 0 | 09000064b91df4f4 | |
| FDA-2007-D-0369-2439 | FDA | FDA-2007-D-0369 | PSG_019927 - Draft Guidance on Ketoconazole | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:21:03Z | 1 | 0 | 09000064b91df4d2 | |
| FDA-2007-D-0369-2453 | FDA | FDA-2007-D-0369 | PSG_021180 - Draft Guidance on Ethinyl Estradiol; Norelgestromin | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:25:18Z | 1 | 0 | 09000064b91e0108 | |
| FDA-2007-D-0369-2435 | FDA | FDA-2007-D-0369 | PSG_018891 - Draft Guidance on Clonidine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:19:51Z | 1 | 0 | 09000064b91df4ca | |
| FDA-2007-D-0369-2441 | FDA | FDA-2007-D-0369 | PSG_020076 - Draft Guidance on Nicotine | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:21:38Z | 1 | 0 | 09000064b91df4d6 | |
| FDA-2007-D-0369-2429 | FDA | FDA-2007-D-0369 | PSG_012283 - Draft Guidance on Chlorthalidone | Other | Guidance | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-04-29T03:59:59Z | 2026-02-27T19:17:46Z | 1 | 0 | 09000064b91df45f | |
| FDA-2026-H-1420-0001 | FDA | FDA-2026-H-1420 | Complaint | Other | Complaint | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T23:42:51Z | 0 | 0 | 09000064b91e3818 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);